Limited Edition Golden Llama is here! Check out how you can get one.
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!
Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers !
Shipping Price Reduction for EU Regions
Cat. No. | Especies | Descripción del producto | Estructura | Pureza | Característica |
---|---|---|---|---|---|
FXI-C52H3 | Rhesus macaque | Rhesus macaque Coagulation factor XI Protein, His Tag (SPR verified) | ![]() |
![]() ![]() |
|
FXI-H52H5 | Human | Human Coagulation factor XI / FXI Protein, His Tag (active enzyme) | ![]() |
![]() ![]() |
Abelacimab captured on Protein A Chip can bind Rhesus macaque Coagulation factor XI, His Tag (Cat. No. FXI-C52H3) with an affinity constant of 22.4 pM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Factor XI concentrate (factor XI deficiency), CSL Behring | Approved | Csl Behring Llc | Australia | Factor XI Deficiency | Csl Behring Llc | 2014-07-01 | Factor XI Deficiency | Details | ||
Human coagulation Factor XI (LFB) | Approved | Lfb Biotechnologies Sas | Hemoleven | EU | Factor XI Deficiency | Lfb Biotechnologies Sas | 1999-07-01 | Factor XI Deficiency | Details | |
Factor XI concentrate (factor XI deficiency), CSL Behring | Approved | Csl Behring Llc | Australia | Factor XI Deficiency | Csl Behring Llc | 2014-07-01 | Factor XI Deficiency | Details | ||
Human coagulation Factor XI (LFB) | Approved | Lfb Biotechnologies Sas | Hemoleven | EU | Factor XI Deficiency | Lfb Biotechnologies Sas | 1999-07-01 | Factor XI Deficiency | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Asundexian | BAY-2433334 | Phase 3 Clinical | Bayer AG | Embolism; Myocardial Infarction; Stroke; Thromboembolism; Ischemic Attack, Transient; Atrial Fibrillation; Hepatic Insufficiency | Details |
Milvexian | BMS-986177; JNJ-70033093; JNJ-3093 | Phase 3 Clinical | Bristol-Myers Squibb Company | Embolism; Contraception; Kidney Diseases; Acute Coronary Syndrome; Stroke; Thromboembolism; Ischemic Attack, Transient; Atrial Fibrillation; Coronary Thrombosis; Thrombosis | Details |
Abelacimab | MAA-868; NOV-12 | Phase 3 Clinical | Novartis Pharma Ag | Pulmonary Embolism; Embolism; Venous Thromboembolism; Neoplasms; Stroke; Thromboembolism; Atrial Fibrillation; Venous Thrombosis | Details |
EP-7041 | EP-7041; HSK36273; HSK-36273; EP7041 | Phase 2 Clinical | Exithera | Blood Coagulation Disorders; Coronavirus Disease 2019 (COVID-19); Thromboembolism; Thrombocytopenia; Thrombosis | Details |
Osocimab | BAY-1213790 | Phase 2 Clinical | Bayer AG | Kidney Diseases; Thromboembolism; Uremia; Kidney Failure, Chronic | Details |
IONIS-FXIRX | FXI-ASO; ISIS-FXIRX; BAY-2306001; IONIS-FXIRX; ISIS-404071; ISIS-416858 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Venous Thromboembolism; Thrombosis | Details |
MK-2060 | MK-2060 | Phase 2 Clinical | Merck Sharp & Dohme Corp | Kidney Diseases; Thromboembolism; Uremia; Kidney Failure, Chronic; Thrombosis | Details |
SHR-2004 | SHR-2004 | Phase 2 Clinical | Venous Thromboembolism; Thromboembolism; Atrial Fibrillation; Dyslipidemias; Venous Thrombosis; Thrombosis | Details | |
KN-060 | KN-060; KN060 | Phase 2 Clinical | Suzhou Alphamab Co Ltd | Thromboembolism | Details |
REGN-9933 | REGN-9933 | Phase 2 Clinical | Venous Thromboembolism | Details | |
Ir-CPI | Ir-CPI | Phase 2 Clinical | Bioxodes SA | Cerebral Hemorrhage | Details |
Fesomersen | ION-957943; IONIS-FXI-LRx; BAY-2976217 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Nephrosis; Thromboembolism | Details |
SHR2285 | SHR-2285 | Phase 2 Clinical | Jiangsu Hengrui Medicine Co Ltd | Embolism; Venous Thromboembolism; Thromboembolism; Venous Thrombosis; Thrombosis | Details |
ONO-7269 | ONO-7269 | Phase 1 Clinical | Ono Pharmaceutical Co Ltd | Cerebral Infarction | Details |
BAY-1831865 | AB-012; BAY-1831865 | Phase 1 Clinical | Aronora Inc | Thrombosis | Details |
ONO-7684 | ONO-7684 | Phase 1 Clinical | Ono Pharmaceutical Co Ltd | Venous Thromboembolism | Details |
BMS-262084 | BMS-262084 | Phase 1 Clinical | Bristol-Myers Squibb Company | Thrombosis | Details |
SRSD-107 | SRSD-107; SRSD107 | Phase 1 Clinical | Sirius Therapeutics Inc | Arterial Thromboembolism; Venous Thromboembolism; Thromboembolism; Cardiovascular Diseases; Thrombosis | Details |
REGN7508 | REGN7508 | Phase 1 Clinical | Details | ||
RBD-4059 | RBD-4059 | Phase 1 Clinical | Suzhou Ribo Life Science Co Ltd | Kidney Failure, Chronic | Details |
BMS-986209 | BMS-986209 | Phase 1 Clinical | Bristol-Myers Squibb Company | Details | |
NIP-003 | NIP003; NIP-003; CRB4101; CRB-4101 | Phase 1 Clinical | National Institutes Of Pharmaceutical Research And Development Co Ltd | Venous Thromboembolism; Thromboembolism; Venous Thrombosis | Details |
Factor XIa Inhibitor (Bayer) | Factor XIa Inhibitor (Bayer) | Phase 1 Clinical | Bayer AG | Blood Coagulation Disorders | Details |
SKB-336 | SKB-336 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Thromboembolism | Details |
SAL-0104 | SAL-0104; SAL0104 | Phase 1 Clinical | Suzhou Genemen Biotech Co Ltd | Embolism; Myocardial Infarction; Venous Thromboembolism; Stroke; Ischemic Attack, Transient; Cardiovascular Diseases; Venous Thrombosis; Thrombosis | Details |
STP122G | STP-122G; STP122G | Phase 1 Clinical | Sirnaomics Biopharmaceuticals (Suzhou) Co Ltd | Embolism and Thrombosis | Details |
Asundexian | BAY-2433334 | Phase 3 Clinical | Bayer AG | Embolism; Myocardial Infarction; Stroke; Thromboembolism; Ischemic Attack, Transient; Atrial Fibrillation; Hepatic Insufficiency | Details |
Milvexian | BMS-986177; JNJ-70033093; JNJ-3093 | Phase 3 Clinical | Bristol-Myers Squibb Company | Embolism; Contraception; Kidney Diseases; Acute Coronary Syndrome; Stroke; Thromboembolism; Ischemic Attack, Transient; Atrial Fibrillation; Coronary Thrombosis; Thrombosis | Details |
Abelacimab | MAA-868; NOV-12 | Phase 3 Clinical | Novartis Pharma Ag | Pulmonary Embolism; Embolism; Venous Thromboembolism; Neoplasms; Stroke; Thromboembolism; Atrial Fibrillation; Venous Thrombosis | Details |
EP-7041 | EP-7041; HSK36273; HSK-36273; EP7041 | Phase 2 Clinical | Exithera | Blood Coagulation Disorders; Coronavirus Disease 2019 (COVID-19); Thromboembolism; Thrombocytopenia; Thrombosis | Details |
Osocimab | BAY-1213790 | Phase 2 Clinical | Bayer AG | Kidney Diseases; Thromboembolism; Uremia; Kidney Failure, Chronic | Details |
IONIS-FXIRX | FXI-ASO; ISIS-FXIRX; BAY-2306001; IONIS-FXIRX; ISIS-404071; ISIS-416858 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Venous Thromboembolism; Thrombosis | Details |
MK-2060 | MK-2060 | Phase 2 Clinical | Merck Sharp & Dohme Corp | Kidney Diseases; Thromboembolism; Uremia; Kidney Failure, Chronic; Thrombosis | Details |
SHR-2004 | SHR-2004 | Phase 2 Clinical | Venous Thromboembolism; Thromboembolism; Atrial Fibrillation; Dyslipidemias; Venous Thrombosis; Thrombosis | Details | |
KN-060 | KN-060; KN060 | Phase 2 Clinical | Suzhou Alphamab Co Ltd | Thromboembolism | Details |
REGN-9933 | REGN-9933 | Phase 2 Clinical | Venous Thromboembolism | Details | |
Ir-CPI | Ir-CPI | Phase 2 Clinical | Bioxodes SA | Cerebral Hemorrhage | Details |
Fesomersen | ION-957943; IONIS-FXI-LRx; BAY-2976217 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Nephrosis; Thromboembolism | Details |
SHR2285 | SHR-2285 | Phase 2 Clinical | Jiangsu Hengrui Medicine Co Ltd | Embolism; Venous Thromboembolism; Thromboembolism; Venous Thrombosis; Thrombosis | Details |
ONO-7269 | ONO-7269 | Phase 1 Clinical | Ono Pharmaceutical Co Ltd | Cerebral Infarction | Details |
BAY-1831865 | AB-012; BAY-1831865 | Phase 1 Clinical | Aronora Inc | Thrombosis | Details |
ONO-7684 | ONO-7684 | Phase 1 Clinical | Ono Pharmaceutical Co Ltd | Venous Thromboembolism | Details |
BMS-262084 | BMS-262084 | Phase 1 Clinical | Bristol-Myers Squibb Company | Thrombosis | Details |
SRSD-107 | SRSD-107; SRSD107 | Phase 1 Clinical | Sirius Therapeutics Inc | Arterial Thromboembolism; Venous Thromboembolism; Thromboembolism; Cardiovascular Diseases; Thrombosis | Details |
REGN7508 | REGN7508 | Phase 1 Clinical | Details | ||
RBD-4059 | RBD-4059 | Phase 1 Clinical | Suzhou Ribo Life Science Co Ltd | Kidney Failure, Chronic | Details |
BMS-986209 | BMS-986209 | Phase 1 Clinical | Bristol-Myers Squibb Company | Details | |
NIP-003 | NIP003; NIP-003; CRB4101; CRB-4101 | Phase 1 Clinical | National Institutes Of Pharmaceutical Research And Development Co Ltd | Venous Thromboembolism; Thromboembolism; Venous Thrombosis | Details |
Factor XIa Inhibitor (Bayer) | Factor XIa Inhibitor (Bayer) | Phase 1 Clinical | Bayer AG | Blood Coagulation Disorders | Details |
SKB-336 | SKB-336 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Thromboembolism | Details |
SAL-0104 | SAL-0104; SAL0104 | Phase 1 Clinical | Suzhou Genemen Biotech Co Ltd | Embolism; Myocardial Infarction; Venous Thromboembolism; Stroke; Ischemic Attack, Transient; Cardiovascular Diseases; Venous Thrombosis; Thrombosis | Details |
STP122G | STP-122G; STP122G | Phase 1 Clinical | Sirnaomics Biopharmaceuticals (Suzhou) Co Ltd | Embolism and Thrombosis | Details |
This web search service is supported by Google Inc.